New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.46 1.12 +1.92%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 11.0% in FY25, against a low of −9.49% in FY24. ROE, at 40.4%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE29.0%7.1%37.9%10.4%−20.1%18.9%18.8%26.5%−39.0%40.4%
ROIC22.1%24.7%29.3%3.7%−5.9%8.0%7.9%9.3%−9.5%11.0%

Debt

Net debt is 2.58× a year’s EBITDA. Debt is 2.44× equity, against 3.03× in FY24.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.4×0.7×0.5×0.9×1.3×1.2×1.3×1.3×3.0×2.4×
Net debt / EBITDA0.1×0.2×−0.2×4.7×9.9×1.5×1.7×1.5×31.8×2.6×

Cash cycle, in days

Customers pay in 86 days, inventory is held 70 days and suppliers are paid in 94. Cash is tied up for 63 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle734554191534253685463
Days to pay suppliers122136107110841081091119494
Days to be paid10411193107737478898186

Per share, from FY16

Since FY16, per share: free cash flow has grown 21.4% a year; revenue has grown 8.23% a year; book value has fallen 0.80% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×2.3×3.4×3.9×5.3×6.2×5.1×5.5×6.2×5.7×
Revenue1.0×1.1×1.2×1.3×1.6×1.8×1.9×1.9×2.0×2.0×
Book value1.0×0.7×0.9×3.1×1.7×1.7×1.5×1.5×0.8×0.9×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
15.59 0.00 13.60 24.25 19.79 0.00 29.05 17.16 100.51 22.27
Piotroski F-Score
8 4 7 6 8 5 3 9 6 6
Altman Z-Score
2.14 1.43 2.28 2.57 2.23 1.57 1.64 5.25 5.40 6.10
P/S ratio
2.28 2.37 2.43 3.33 2.99 3.29 4.19 3.76 4.85 5.11
P/FCF ratio
8.54 8.22 8.63 12.88 9.09 10.53 14.84 13.88 23.90 53.90
Altman Z″-Score (non-manufacturers)
2.01 0.57 2.71 2.26 2.41 1.30 2.37 6.36 5.66 6.36
Beneish M-Score
(2.69) (3.75) (2.70) (2.76) (2.84) (3.30) (1.97) (2.83) (3.05) (2.03)
P/Operating CF
55.58 25.83 25.67 46.56 34.13 41.75 50.18 23.88 90.29 68.84
P/B ratio
5.93 7.00 3.70 4.95 3.85 3.70 2.12 6.01 8.51 6.08
EV/Sales
2.99 3.18 3.04 3.99 3.58 4.11 5.38 3.70 4.91 5.13
EV/EBITDA
10.81 125.67 7.51 10.23 8.84 49.85 20.95 12.64 17.23 15.83
EV/FCF
11.22 11.01 10.80 15.40 10.90 13.15 19.09 13.65 24.17 54.10
Current Ratio
1.26 1.25 1.43 1.25 1.52 1.58 1.60 1.66 1.55 1.55
Net Debt/EBITDA
2.58 31.77 1.51 1.67 1.47 9.93 4.66 (0.21) 0.19 0.06
Debt/Equity
2.44 3.03 1.35 1.26 1.24 1.34 0.90 0.52 0.67 0.41
ROE
40.43% (39.01%) 26.48% 18.85% 18.93% (20.13%) 10.45% 37.88% 7.14% 28.97%
ROA
7.72% (9.53%) 8.36% 6.14% 6.14% (7.26%) 4.17% 14.36% 2.99% 13.62%
ROIC
11.01% (9.49%) 9.26% 7.88% 7.96% (5.90%) 3.74% 29.33% 24.67% 22.13%
Return on Tangible Assets
52.19% (68.09%) 49.68% 54.37% 40.10% (53.04%) 19.88% 40.70% 9.78% 45.28%
Average Days of Receivables
86.44 81.21 88.57 78.17 73.72 72.98 107.29 92.98 110.68 104.14
Earnings Yield
6.41% (7.81%) 7.35% 4.12% 5.05% (6.45%) 3.44% 5.83% 0.99% 4.49%
Free Cash Flow Yield
11.71% 12.16% 11.59% 7.76% 11.00% 9.49% 6.74% 7.20% 4.18% 1.86%
Free Cash Flow per Share
6.32 6.88 6.11 5.61 6.86 5.89 4.32 3.74 2.57 1.10
Book value per Share
9.10 8.08 14.25 14.61 16.21 16.78 30.32 8.65 7.20 9.78
Free Cash Flow
12,845.00 13,942.00 12,651.00 11,948.00 15,234.00 13,299.00 7,374.00 6,115.00 4,220.00 1,843.00
EV/EBIT
15.45 0.00 16.19 23.85 20.51 0.00 28.30 13.99 19.88 16.86
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026